ArticleVaccine2020
Archetype analysis of older adult immunization decision-making and implementation in 34 countries.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Stakeholder readiness in the evolving adult vaccine market.iScience · 2025Article
- Seasonal Influenza Vaccination Uptake Among Australian Healthcare Professionals: An Archetype for Success.Vaccines · 2025Article
- Overview of adult immunization in Italy: Successes, lessons learned and the way forward.Human vaccines & immunotherapeutics · 2024Review
- Role of new vaccinators/pharmacists in life-course vaccination.Annals of medicine · 2024Review
- Invasive meningococcal disease in older adults: current perspectives and call for action.European geriatric medicine · 2024Review
- Article
- Review
- Socioeconomic and fiscal returns of expanded investment in immunization: a case for life-course vaccination in Colombia.Health affairs scholar · 2024Article
- Closing the pneumococcal conjugate vaccine (PCV) introduction gap: an archetype analysis of last-mile countries.Global health action · 2023Article
- A review of factors influencing vaccination policies and programs for older adults globally.Human vaccines & immunotherapeutics · 2023Review
- Healthy ageing: Herpes zoster infection and the role of zoster vaccination.NPJ vaccines · 2023Review
- Assessing the health burden of vaccine-preventable infections in European adults: challenges and opportunities translated into action.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Intention to Vaccinate against COVID-19 among Young Adults: The Role of Conspiratorial Thinking.Vaccines · 2023Article
- Validation of the Vaccination Trust Indicator (VTI) in a multi-country survey of adult vaccination attitudes.PLOS global public health · 2023Article
- Vaccination coverage among older adults: a population-based study in India.Bulletin of the World Health Organization · 2022Article
- Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe.Frontiers in public health · 2022Review
- A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.Vaccine · 2021Article
- Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature.Vaccines · 2021Review
- Determinants of policy and uptake of national vaccine programs for pregnant women: results of mixed method study from Spain, Italy, and India.Human vaccines & immunotherapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global population of adults over 65 years of age is growing rapidly and is expected to double by 2050. Countries will face substantial health, economic and social burden deriving from vaccine-preventable diseases (VPDs) such as influenza, pneumonia and herpes zoster in older adults. It will be essential that countries utilize several public health strategies, including immunization. Understanding the different approaches countries have taken on adult immunization could help provide future learnings and technical support for adult vaccines within life-course immunization strategies. In this study, we describe the priorities and approaches that underlie adult immunization decision-making and implementation processes in 32 high-and-middle-income countries and two territories ("34 countries") who recommend adult vaccines in their national schedule. We conducted an archetype analysis based on a subset of two dozen indicators abstracted from a larger database. The analysis was based on a mixed-methods study, including results from 120 key informant interviews in six countries and a landscape review of secondary data from 34 countries. We found four distinct archetypes: disease prevention-focused; health security-focused; evolving adult focus; and, child-focused and cost-sensitive. The highest performing countries belonged to the disease prevention-focused and health security archetypes, although there was a range of performance within each archetype. Considering common barriers and facilitators of decision-making and implementation of adult vaccines within a primary archetype could help provide a framework for strategies to support countries with similar needs and approaches. It can also help in developing context-specific policies and guidance, including for countries prioritizing adult immunization programs in light of COVID-19. Further research may be beneficial to further refine archetypes and expand the understanding of what influences success within them. This can help advance policies and action that will improve vaccine access for older adults and build a stronger appreciation of the value of immunization amongst a variety of stakeholders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.